WAYNE, Pa., March 1, 2016 /PRNewswire/ -- LifeScan, Inc., a business within the Johnson & Johnson Diabetes Care Companies and a world leader in blood glucose monitoring, today announced a strategic collaboration through its affiliate Cilag GmbH International with WellDoc Corporation (WellDoc) to advance mobile solutions that can empower Type 2 diabetes patients with real time data and information to improve their health outcomes. In addition, Johnson & Johnson Innovation - JJDC, Inc. (JJDC) participated with other investors in WellDoc's Series B financing. This new relationship exemplifies Johnson & Johnson's cross-sector strategy of collaborating with a wide range of technology companies to create new ways that help people live longer, healthier lives.
"We are continuously working to empower diabetes patients by developing and integrating innovative technologies that can improve both daily experiences and long-term health," said Val Asbury, Worldwide President, LifeScan, Inc. "This exciting collaboration bridges our strong history serving diabetes patients and their healthcare team with WellDoc's innovative diabetes management platform that has been shown to improve health outcomes. By working together, we look forward to advancing new solutions."
Through the collaboration both companies will work to integrate LifeScan's newly launched OneTouch Verio Flex™ blood glucose monitoring system with built-in Bluetooth® Smart Technology and OneTouch Reveal® mobile application with WellDoc's BlueStar® diabetes management platform and mobile application, the first mobile prescription therapy approved by the U.S. Food and Drug Administration for Type 2 diabetes. OneTouch Verio Flex™ features ColorSure™ technology – a simple, accurate and easy-to-use meter that takes the guesswork out of understanding blood sugar test results for people with diabetes. The integration would provide patients additional smart monitoring tools and real-time motivational, behavioral and educational coaching, which clinical studies have shown improve patient health.
Currently, there are an estimated 21 million people diagnosed with Type 2 diabetes in the U.S. and many don't test their blood sugar regularly or as recommended by their healthcare professional. In a clinical trial, WellDoc showed that when patients used its diabetes management platform for a 12-month period they had a 1.9 percent decline in glycated hemoglobin level over 12 months compared with a 0.7 percent decrease in the usual care group.*
*Quinn CC et al. Diabetes Care. 2011;34: 1934-1942
About LifeScan, Inc.
LifeScan, Inc. is part of the Johnson & Johnson Diabetes Care Companies. With a shared vision of creating a world without limits for people with diabetes, the Johnson & Johnson Diabetes Care Companies is a collaboration of Johnson & Johnson companies dedicated to diabetes and includes LifeScan, Inc., a world leader in blood glucose monitoring; Animas Corporation, maker of innovative insulin delivery systems; and Calibra Medical, Inc., developer of a unique 3-day wearable insulin patch pump. In the US, LifeScan, Inc. is the leading maker of blood glucose monitoring systems and its OneTouch® brand products are recommended by more endocrinologists and primary care physicians than any other brand. Globally, more than 15 million people depend on OneTouch® brand products for simple testing and accurate results to help them manage their diabetes. For more information visit: www.OneTouch.com.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 related to a new collaboration and product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of LifeScan, Inc., Cilag GmbH International, Johnson & Johnson Innovation - JJDC, Inc., and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges and uncertainties inherent in new product development, including the uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; the ability of the company to successfully execute strategic plans; changes to applicable laws and regulations, including global health care reforms and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Johnson & Johnson nor any of its affiliated companies undertakes to update any forward- looking statement as a result of new information or future events or developments.
SOURCE LifeScan, Inc.